Latest News and Press Releases
Want to stay updated on the latest news?
-
WILMETTE, Ill., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
-
WILMETTE, Ill., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
-
Camsirubicin Phase 1b Trial Currently at 5th Dose-Level (650 mg/m2), Generating Encouraging ResultsMNPR-101 Radiopharma Program Advancing Toward First-in-Human Studies WILMETTE, Ill., Aug. 10, 2023...
-
WILMETTE, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for...
-
Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore
WILMETTE, Ill., July 11, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today...
-
WILMETTE, Ill., June 21, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
-
WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
-
Patient in 520 mg/m2 cohort, previously unresectable, experienced tumor shrinkage and had tumor resected following camsirubicin treatment 3 of 3 patients in the 520 mg/m2 cohort achieved stable...
-
Camsirubicin Phase 1b DoseEscalation Trial Enrolling 5th DoseLevel Cohort (650 mg/m2)MNPR-101 RIT Shows Promising Imaging and Therapeutic Preclinical Study ResultsWILMETTE, Ill., May 11, 2023 (GLOBE...
-
WILMETTE, Ill., March 28, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...